Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Tukholmankatu 8, 00290, Helsinki, Finland.
Minerva Foundation Institute for Medical Research, Tukholmankatu 8, 00290, Helsinki, Finland.
Clin Epigenetics. 2024 Nov 18;16(1):160. doi: 10.1186/s13148-024-01767-y.
Assessment of breast cancer (BC) risk generally relies on mammography, family history, reproductive history, and genotyping of major mutations. However, assessing the impact of environmental factors, such as lifestyle, health-related behavior, or external exposures, is still challenging. DNA methylation (DNAm), capturing both genetic and environmental effects, presents a promising opportunity. Previous studies have identified associations and predicted the risk of BC using DNAm in blood; however, these studies did not distinguish between genetic and environmental contributions to these DNAm sites. In this study, associations between DNAm and BC are assessed using paired twin models, which control for shared genetic and environmental effects, allowing testing for associations between DNAm and non-shared environmental exposures and behavior.
Pre-diagnosis blood samples of 32 monozygotic (MZ) and 76 dizygotic (DZ) female twin pairs discordant for BC were collected at the mean age of 56.0 years, with the mean age at diagnosis 66.8 years and censoring 75.2 years. We identified 212 CpGs (p < 6.4*10) and 15 DMRs associated with BC risk across all pairs using paired Cox proportional hazard models. All but one of the BC risks associated with CpGs were hypomethylated, and 198/212 CpGs had their DNAm associated with BC risk independent of genetic effects. According to previous literature, at least five of the top CpGs were related to estrogen signaling. Following a comprehensive two-sample Mendelian randomization analysis, we found evidence supporting a dual causal impact of DNAm at cg20145695 (gene body of NXN, rs480351) with increased risk for estrogen receptor positive BC and decreased risk for estrogen receptor negative BC.
While causal effects of DNAm on BC risk are rare, most of the identified CpGs associated with the risk of BC appear to be independent of genetic effects. This suggests that DNAm could serve as a valuable biomarker for environmental risk factors for BC, and may offer potential benefits as a complementary tool to current risk assessment procedures.
乳腺癌 (BC) 风险的评估通常依赖于乳房 X 光检查、家族史、生殖史和主要突变的基因分型。然而,评估环境因素(如生活方式、健康相关行为或外部暴露)的影响仍然具有挑战性。DNA 甲基化 (DNAm) 既能捕捉遗传因素,又能捕捉环境因素,是一种很有前途的方法。以前的研究已经使用血液中的 DNAm 识别出与 BC 相关的关联并预测了 BC 的风险;然而,这些研究并没有区分这些 DNAm 位点的遗传和环境贡献。在这项研究中,我们使用配对双胞胎模型评估了 DNAm 与 BC 之间的关联,该模型控制了共同的遗传和环境效应,从而可以检测 DNAm 与非共享环境暴露和行为之间的关联。
在平均年龄为 56.0 岁时,采集了 32 对同卵 (MZ) 和 76 对异卵 (DZ) 女性双胞胎中 32 对 MZ 和 76 对 DZ 女性双胞胎的预诊断血液样本,诊断时的平均年龄为 66.8 岁,截止年龄为 75.2 岁。我们使用配对 Cox 比例风险模型在所有双胞胎中鉴定出 212 个与 BC 风险相关的 CpG(p < 6.4*10)和 15 个 DMR。所有与 CpG 相关的 BC 风险相关的 CpG 中,除一个外,其余均呈低甲基化状态,212 个 CpG 中有 198 个与 BC 风险相关,不受遗传效应影响。根据以往的文献,前 212 个 CpG 中至少有 5 个与雌激素信号有关。经过全面的两样本 Mendelian 随机化分析,我们发现证据支持 cg20145695(NXN 基因体,rs480351)处的 DNAm 具有双重因果作用,与雌激素受体阳性 BC 的风险增加和雌激素受体阴性 BC 的风险降低有关。
虽然 DNAm 对 BC 风险的因果效应很少见,但与 BC 风险相关的大多数鉴定出的 CpG 似乎独立于遗传效应。这表明 DNAm 可以作为 BC 环境风险因素的有价值的生物标志物,并可能作为当前风险评估程序的补充工具提供潜在益处。